As you know, there is no cure, yet. There are many studies going on and the results are
    very promising. They are getting closing to better understand the disease and thus design
    a cure.

    These drugs approved for the treatment of the relapsing-remitting forms of MS are
    considered disease-modulating drugs. They help control the symptoms and some of them
    have recently shown certain positive effect that results in a slow repair of the affected
    nerve. The one to use depends on your doctor's decision on what could work better for
    you.

    Aubagio® is manufactured by Genzyme, a Sanofi company. It was approved to treat
    relapsing forms of MS (relapsing-remitting MS and secondary progressive MS). This is the
    second oral disease-modifying therapy approved for the treatment of multiple sclerosis.
    Two doses (7mg and 14 mg) have been approved. Aubagio can inhibit a key enzyme
    required by white blood cells (lymphocytes), reducing the proliferation of T and B immune
    cells active in MS and also inhibiting the production of immune messenger chemicals by T
    cells. It can reduce the total volume of tissue damage and active areas of damage as seen
    on scanning images, can reduce the annual relapse rate, and can reduce the disability
    progression. More information on www.aubagio.com

    Avonex® (interferon beta 1-a) manufactured by Biogen Idec, is administer by
    intramuscular injection once a week. It has shown to reduce the severity and frequency of
    MS attacks and reduce the lesions (active or new) in the brain.

    Betaseron® (interferon beta 1-b) manufactured by Berlex Laboratories, Inc., Extavia®
    (Interferón beta 1-b) manufactured by Novartis, Incis administer by subcutaneous
    (underneath the skin) injection every other day. It has shown to reduce the severity and
    frequency of MS attacks and reduce the lesions (active or new) in the brain.

    Copaxone® (glatiramer acetate) manufactured by TEVA Neuroscience, Inc., is administer
    every day by subcutaneous injection. It has shown to reduce the frequency of MS attacks
    and reduce the lesions (active or new) in the brain.

    Gilenya® (Fingolimod) is produced by Novartis. It was the first oral treatment to be
    approved for the relapsing forms of MS. The drug seems to inhibit the migration of the
    immune cells to the brain and spine forcing them to stay in the lymphatic nodules.

    Rebif® (interferon beta 1-a) manufactured by Serono, Inc., is administer three times a
    week by subcutaneous injection. It has shown to reduce the frequency of MS attacks and
    reduce the lesions (active or new) in the brain and may slow progression of disability.

    Novantrone® (mitoxantrone) manufactured by Serono, Inc., is administered four times a
    year by IV infusion in a medical facility. It is powerful immune system suppressor approved
    to be used in worsening relapsing-remitting ms as well as secondary progressive MS and
    all progressive forms of the MS. It has shown to reduce the frequency of MS attacks and
    reduce the lesions (active or new) in the brain and may slow progression of disability.

    Tecnifera®(BG12 or dimethyl fumarate) manufactured by Biogen Idec., is an oral capsule
    with progressive initial doses starting at 120 mg twice a day for 7 days and continuing to
    240mg twice a day (maintenance dose). It was approve for the relapsing forms of MS. It
    has been shown to reduce the annual rate of MS attacks and the lesions (active and new)
    in the brain. More information in Tecnifera.com

    Tysabri® (natalizumab) manufactured by Biogen Idec and Elan Pharmaceuticals, by iv
    infusion every four weeks. Tysabri is generally recommended for patients who have had
    inadequate response to, or are unable to tolerate, other approved MS therapies. It is
    approved as a monotherapy, not to be combined with other immune system-modifying
    agents, and is not recommended for individuals who have weakened immune systems. It
    was first withdrawn after three patients developed a serious viral infection of the brain. It is
    approved to be use with a special restricted distribution program
    See questions and answers on Tysabri from NMSS website:
    http://www.nationalmssociety.org



    Besides the disease-modifying drugs, there are other therapies available for specific
    symptoms like fatigue, pain, depression, spasticity, occupational therapy (for work) and
    cognitive therapy (for memory problems) among others. You should talk to your doctor to
    coordinate the therapy that is appropriate for you.

    See  Latest News



Disclaimer
WE WILL NOT BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIFFICULTY IN USE,
INACCURACY OR INCOMPLETENESS OF INFORMATION, USE OF THIS INFORMATION OR
RESULTS ARISING FORM THE USE OF IT, COMPUTER VIRUSES, MALICIOUS CODE, LOSS OF
DATA, COMPATIBILITY ISSUES, OR OTHERWISE. WE WILL NOT BE LIABLE TO YOU OR ANY
THIRD PARTY FOR ANY DIRECT, INDIRECT, SPECIAL INCIDENTAL, CONSEQUENTIAL,
EXEMPLARY OR PUNITIVE DAMAGES (INCLUDING LOST PROFITS, LOST DATA. COST TO
PROCURE REPLACEMENT SERVICES OR GOODS, OR BUSINESS OPPORTUNITIES) ARISING OUT
OF YOUR ACCESS TO OR USE OF OUR SITE, OR ANY OTHER LINK WE PROVIDE TO ANOTHER
SITE, OR ANY ACTS, OMISSIONS, DEFECTS, SECURITY BREACHES, OR DELAYS, REGARDLESS
OF THE BASIS OF THE CLAIM OR IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGE OR LOSS. EACH PERSON IS RESPONSIBLE TO CONSULT THE INFORMATION WITH
THEIR PHYSICIAN.







Maria A Reyes-Velarde,
MD, MPH
hablemosdeem.com
Treatment
Permission to use/copy any part of the site
"HABLEMOS DE ESCLEROSIS MULTIPLE" must
be granted by the author
hablemosdeem.com


©2001-2013maria a. reyes-velarde
All rights reserved